ALT Share Price Performance
US$4.81
-3.87 (-44.59%)
Price US$4.81
Share Pricen/a
Altimmune, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 37 Fair Values set on narratives written by author
ALT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Altimmune, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.80
- -338,920.00%
- -419,575.00%
- 7.8%
About ALT
- Founded
- 1997
- Employees
- 59
- CEO
- WebsiteView website
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
